Registry of Lobbyists
Version 2 of 43 (2007-08-23 to 2008-03-30) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
Janssen Ortho Inc
19 Green Belt Drive Toronto, ON M3C 1L9 Canada |
| Telephone number: | 416-449-9444 |
| Fax number: | 416-449-2658 |
| Responsible officer name and position during the period of this registration: | Chris Halyk, General Manager |
| Description of activities: | Research based pharmaceutical company |
| The client is a subsidiary of the following parent companies: |
Johnson & Johnson
One Johnson & Johnson Plaza New Brunswick, NJ United States of America 08933 |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | Penny Albright |
| Position title: | VP Government & Health Economics |
| Public offices held: | No |
| Name: | Lesia Babiak |
| Position title: | Director, Federal Affairs & Health Policy |
| Public offices held: | No |
| Name: | Fiona Dunbar |
| Position title: | VP Clinical Affairs |
| Public offices held: | No |
| Name: | Cathy Lau |
| Position title: | VP Regulatory Affairs |
| Public offices held: | No |
| Name: | Veera Rastogi |
| Position title: | VP Law |
| Public offices held: | Yes |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Canadian International Development Agency (CIDA), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Members of the House of Commons, Patented Medicine Prices Review Board (PMPRB) | ||||||||||||||||
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||||||||||||||
| Subject Matter: Areas of Concern: | Health, Industry, Intellectual Property, International Trade, Science and Technology | ||||||||||||||||
| Subject Matter: Retrospective: | In two months preceding the date of filing, officers of Janssen-Ortho have been engaged in lobbying activities related to: a. The House of Commons Standing Committee on Health's (HESA) study of the Status of and progress accomplished under the Common Drug Review (CDR);b. The on-going work of the Patented Medicine Prices Review Board as it relates to the pricing of Janssen-Ortho molecules and drugs;c. Industry Canada's Regulations Amending the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") and Health Canada's Regulations Amending the Food and Drug Regulations. | ||||||||||||||||
| Subject Matter: Prospective: | In the next six months, officers of Janssen-Ortho will be engaged in lobbying activities related to: a. The House of Commons Standing Committee on Health's (HESA) study of the Status of and progress accomplished under the Common Drug Review (CDR);b. The on-going work of the Patented Medicine Prices Review Board as it related to the pricing of Janssen-Ortho molecules and drug. c. Health Canada's proposal to add the drug tramadol to the Controlled Drugs and Substance Act (CDSA) and the Schedule of the Narcotic Control Regulations (NCR). | ||||||||||||||||
Details Regarding the Identified Subject Matter
|
|||||||||||||||||